标题
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
作者
关键词
-
出版物
IMMUNOLOGY AND CELL BIOLOGY
Volume 90, Issue 1, Pages 85-94
出版商
Wiley
发表日期
2011-11-29
DOI
10.1038/icb.2011.100
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines
- (2017) Marielle Dejligbjerg et al. Cancer Biomarkers
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
- (2011) R. L. Piekarz et al. BLOOD
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
- (2011) P N Munster et al. BRITISH JOURNAL OF CANCER
- A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma
- (2011) John D. Hainsworth et al. CANCER INVESTIGATION
- Entinostat for treatment of solid tumors and hematologic malignancies
- (2011) Jeffrey Knipstein et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor
- (2011) Yanis Boumber et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Histone Deacetylases 9 and 10 Are Required for Homologous Recombination
- (2011) Shweta Kotian et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Autophagic and Apoptotic Effects of HDAC Inhibitors on Cancer Cells
- (2011) Hidemi Rikiishi JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
- (2011) Mark Kirschbaum et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors
- (2011) Giuseppe Giaccone et al. JOURNAL OF CLINICAL ONCOLOGY
- Unfolded protein response in cancer: the Physician's perspective
- (2011) Xuemei Li et al. Journal of Hematology & Oncology
- Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival
- (2011) Stamatios Theocharis et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung
- (2011) Yoshihiro Minamiya et al. LUNG CANCER
- Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo
- (2011) G. Dasmahapatra et al. MOLECULAR CANCER THERAPEUTICS
- A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03
- (2011) Fabio M. Iwamoto et al. NEURO-ONCOLOGY
- Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells
- (2011) Luca A. Petruccelli et al. PLoS One
- Histone deacetylases as regulators of inflammation and immunity
- (2011) Melanie R. Shakespear et al. TRENDS IN IMMUNOLOGY
- Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma
- (2010) Ruben Niesvizky et al. CANCER
- A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy
- (2010) Peter M. Wilson et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors
- (2010) M. G. Fakih et al. CLINICAL CANCER RESEARCH
- Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours
- (2010) Helen J. Mackay et al. EUROPEAN JOURNAL OF CANCER
- The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
- (2010) Paul A Marks EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance
- (2010) Wenlin Shao et al. INTERNATIONAL JOURNAL OF CANCER
- Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
- (2010) Michael Dickinson et al. INVESTIGATIONAL NEW DRUGS
- Histone Deacetylase Inhibitors Activate NF-κB in Human Leukemia Cells through an ATM/NEMO-related Pathway
- (2010) Roberto R. Rosato et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Lucanthone Is a Novel Inhibitor of Autophagy That Induces Cathepsin D-mediated Apoptosis
- (2010) Jennifer S. Carew et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
- (2010) Sean J. Whittaker et al. JOURNAL OF CLINICAL ONCOLOGY
- Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study
- (2010) Anne M. Traynor et al. Journal of Thoracic Oncology
- Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
- (2010) Suresh S. Ramalingam et al. Journal of Thoracic Oncology
- Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)
- (2010) Gregory A. Otterson et al. Journal of Thoracic Oncology
- Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma
- (2010) Sundar Jagannath et al. LEUKEMIA RESEARCH
- MS-275 Sensitizes TRAIL-Resistant Breast Cancer Cells, Inhibits Angiogenesis and Metastasis, and Reverses Epithelial-Mesenchymal Transition In vivo
- (2010) R. K. Srivastava et al. MOLECULAR CANCER THERAPEUTICS
- Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining
- (2010) Kyle M Miller et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Identification of Histone Deacetylase 3 as a Biomarker for Tumor Recurrence Following Liver Transplantation in HBV-Associated Hepatocellular Carcinoma
- (2010) Li-Ming Wu et al. PLoS One
- HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
- (2010) O. Khan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Apoptosis in cancer: Key molecular signaling pathways and therapy targets
- (2009) Claudia Burz et al. ACTA ONCOLOGICA
- A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma
- (2009) Monica Galli et al. ANNALS OF HEMATOLOGY
- Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
- (2009) L. R. Molife et al. ANNALS OF ONCOLOGY
- HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells
- (2009) C. Urbich et al. BLOOD
- A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma
- (2009) A Rocca et al. BRITISH JOURNAL OF CANCER
- Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma
- (2009) Michael Dickinson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)
- (2009) Deborah Bradley et al. CANCER
- Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis
- (2009) Susan Fotheringham et al. CANCER CELL
- Biomarkers for predicting clinical responses to HDAC inhibitors
- (2009) Lindsay Stimson et al. CANCER LETTERS
- The Critical Role of the Class III Histone Deacetylase SIRT1 in Cancer
- (2009) T. Liu et al. CANCER RESEARCH
- Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
- (2009) A. I. Daud et al. CLINICAL CANCER RESEARCH
- Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
- (2009) A. Badros et al. CLINICAL CANCER RESEARCH
- PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF- B Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells
- (2009) S. Bhalla et al. CLINICAL CANCER RESEARCH
- Targeting of HDAC8 and investigational inhibitors in neuroblastoma
- (2009) Ina Oehme et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A phosphorylation-acetylation switch regulates STAT1 signaling
- (2009) O. H. Kramer et al. GENES & DEVELOPMENT
- In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
- (2009) E. M. Ocio et al. HAEMATOLOGICA
- A phase 2 study of vorinostat in acute myeloid leukemia
- (2009) E. W. Schaefer et al. HAEMATOLOGICA
- Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells
- (2009) Cristian Bellodi et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
- (2009) Evanthia Galanis et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma
- (2009) Axel Hauschild et al. MELANOMA RESEARCH
- HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
- (2009) D. C. Marchion et al. MOLECULAR CANCER THERAPEUTICS
- Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation
- (2009) E Borbone et al. ONCOGENE
- Expression of Hypoxia-Inducible Factor-1α, Histone Deacetylase 1, and Metastasis-Associated Protein 1 in Pancreatic Carcinoma
- (2009) Kotaro Miyake et al. PANCREAS
- Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors
- (2008) Jung-Hyun Park et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells
- (2008) R. Rao et al. BLOOD
- Histone deacetylase inhibitors and genomic instability
- (2008) Grégory Eot-Houllier et al. CANCER LETTERS
- HDAC expression and clinical prognosis in human malignancies
- (2008) Wilko Weichert CANCER LETTERS
- HDAC family: What are the cancer relevant targets?
- (2008) Olaf Witt et al. CANCER LETTERS
- Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma
- (2008) V. R. Fantin et al. CANCER RESEARCH
- A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors
- (2008) N. L. Steele et al. CLINICAL CANCER RESEARCH
- Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma
- (2008) L. Ellis et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
- (2008) T. H. Luu et al. CLINICAL CANCER RESEARCH
- A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
- (2008) Susan C. Modesitt et al. GYNECOLOGIC ONCOLOGY
- Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
- (2008) L Marquard et al. HISTOPATHOLOGY
- Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
- (2008) Robert P. Whitehead et al. INVESTIGATIONAL NEW DRUGS
- Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma
- (2008) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
- (2008) A. Miyanaga et al. MOLECULAR CANCER THERAPEUTICS
- Deletion of Histone Deacetylase 3 Reveals Critical Roles in S Phase Progression and DNA Damage Control
- (2008) Srividya Bhaskara et al. MOLECULAR CELL
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
- Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist
- (2008) A. J. Frew et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas
- (2008) Omar Khan et al. Nature clinical practice. Oncology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now